Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...

Bristol-Myers Squibb (BMY) to announce Q4 earnings on February 6th. Analysts expect $1.47 EPS on $11.56B revenue.

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment. The ...

Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...

Christopher Boerner; Chairman of the Board, Chief Executive Officer, Chief Operating Officer; Bristol-Myers Squibb Co David Elkins; Executive Vice President, Chief Financial Officer, Member of the ...